Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule experimental drug classified chemically as a nitrobenzene derivative containing a phosphoryl group linked to hydroxy and nitrophenoxy moieties. It has the molecular formula C16H23N2O8P and an average molecular weight of approximately 402.34 g/mol. There is no available information on its mechanism of action, therapeutic indications, or clinical use. It is not approved for any medical condition and has no recorded patents or marketed brand names. The drug appears to be in an early stage of research with no clinical trials reported beyond phase 0 or preclinical status.[1][2][3][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-{4-[hydroxy-(4-nitro-phenoxy)-phosphoryl]-butyrylamino}-hexanoic acid.